JP2005518344A5 - - Google Patents

Download PDF

Info

Publication number
JP2005518344A5
JP2005518344A5 JP2003536383A JP2003536383A JP2005518344A5 JP 2005518344 A5 JP2005518344 A5 JP 2005518344A5 JP 2003536383 A JP2003536383 A JP 2003536383A JP 2003536383 A JP2003536383 A JP 2003536383A JP 2005518344 A5 JP2005518344 A5 JP 2005518344A5
Authority
JP
Japan
Prior art keywords
seq
binding protein
polypeptide
residues
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003536383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005518344A (ja
JP4443923B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/032717 external-priority patent/WO2003033653A2/en
Publication of JP2005518344A publication Critical patent/JP2005518344A/ja
Publication of JP2005518344A5 publication Critical patent/JP2005518344A5/ja
Application granted granted Critical
Publication of JP4443923B2 publication Critical patent/JP4443923B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003536383A 2001-10-15 2002-10-15 親和性向上剤 Expired - Fee Related JP4443923B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32883501P 2001-10-15 2001-10-15
US34188101P 2001-12-21 2001-12-21
PCT/US2002/032717 WO2003033653A2 (en) 2001-10-15 2002-10-15 Affinity enhancement agents

Publications (3)

Publication Number Publication Date
JP2005518344A JP2005518344A (ja) 2005-06-23
JP2005518344A5 true JP2005518344A5 (enExample) 2006-01-05
JP4443923B2 JP4443923B2 (ja) 2010-03-31

Family

ID=26986533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003536383A Expired - Fee Related JP4443923B2 (ja) 2001-10-15 2002-10-15 親和性向上剤

Country Status (13)

Country Link
US (1) US20030113333A1 (enExample)
EP (1) EP1444267B1 (enExample)
JP (1) JP4443923B2 (enExample)
KR (1) KR101027889B1 (enExample)
CN (1) CN1604910A (enExample)
AU (1) AU2002335808B2 (enExample)
BR (1) BR0213284A (enExample)
CA (1) CA2463616C (enExample)
IL (1) IL161417A0 (enExample)
MX (1) MXPA04003533A (enExample)
PL (1) PL374426A1 (enExample)
RU (1) RU2004114878A (enExample)
WO (1) WO2003033653A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US6346454B1 (en) * 1999-01-12 2002-02-12 Agere Systems Guardian Corp. Method of making dual damascene interconnect structure and metal electrode capacitor
US20040018557A1 (en) * 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20050003403A1 (en) * 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
CA2531118C (en) * 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
CN101171034B (zh) 2005-03-03 2014-06-18 免疫医疗公司 人源化l243抗体
AU2009239491B2 (en) 2008-04-21 2014-07-17 Lawrence Livermore National Security, Llc Selective high-affinity polydentate ligands and methods of making such
US9050375B2 (en) * 2009-07-06 2015-06-09 Hoffmann-La Roche, Inc. Bi-specific digoxigenin binding antibodies
US9264453B2 (en) 2013-11-08 2016-02-16 At&T Mobility Ii Llc Front end processor for short message service centers
AU2024233139A1 (en) * 2023-03-03 2025-08-28 Oncoone Research & Development Gmbh Improved bispecific anti-tumor antigen/anti-hsg antibodies for pre-targeting of hyperproliferative disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6027725A (en) * 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
CA2145278C (en) * 1992-09-25 2009-03-10 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5989830A (en) * 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US6254868B1 (en) * 1996-03-20 2001-07-03 Immunomedics, Inc. Glycosylated humanized B-cell specific antibodies
WO1997038102A1 (en) * 1996-04-04 1997-10-16 Unilever Plc Multivalent and multispecific antigen-binding protein
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7074405B1 (en) * 1998-06-22 2006-07-11 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
PL372144A1 (en) * 2001-12-26 2005-07-11 Immunomedics, Inc. Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains

Similar Documents

Publication Publication Date Title
JP2021502810A5 (enExample)
RU2004122702A (ru) Способы получения полиспецифичных, поливалентных средств из vh и vl доменов
CN110835371A (zh) 抗ccr8单克隆抗体及其应用
JP2005514030A5 (enExample)
JP2003501401A (ja) B細胞をターゲットとする抗体を使用する自己免疫疾患に対する免疫療法
JP2020508691A5 (enExample)
EP3245224B1 (en) Il-17a-binding polypeptides
JPH08510376A (ja) 新規な抗−ガン胎児性抗原キメラ抗体一族
JP2009521909A5 (enExample)
CN101903402A (zh) 抗tl1a的人源化抗体
JP2010511388A5 (enExample)
JP2008515446A5 (enExample)
WO2013174264A1 (zh) 抗BLyS抗体
JP2008535475A5 (enExample)
JP2023553694A5 (enExample)
JP2025512865A5 (enExample)
CA2598510A1 (en) Q3 sparc deletion mutant and uses thereof
JP2008521426A5 (enExample)
CN116284405B (zh) 靶向cd150蛋白的纳米抗体及其应用
JP2025530888A5 (enExample)
JP2024023268A5 (enExample)
JP7590785B2 (ja) ヒト化抗IL-4Rα単一ドメイン抗体及びその使用
CA2463616A1 (en) Affinity enhancement agents
WO2020119707A1 (zh) 抗il-17a抗体及其应用
CN117860786B (zh) 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途